Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Facing Calls For Compulsory Licensing, Roche To Provide Fuzeon In Korea Under Compassionate Access Program

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Nearly five years after refusing to supply its antiretroviral Fuzeon (enfuvirtide) to HIV/AIDS patients in South Korea due to pricing issues, Roche Korea says it will now provide the medication through its compassionate access program
Advertisement

Related Content

Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
Roche Signs First In-licensing Deal In Korea With DigitalBiotech For Alzheimer's Disease Candidate
Seoul Court Overturns Health Ministry's 14-Percent Price Cut On Novartis' Glivec
Seoul Court Overturns Health Ministry's 14-Percent Price Cut On Novartis' Glivec
Korea Cuts Novartis’ Glivec Price By 14 Percent - Tip Of The Iceberg  For MNCs In Korea?
South Korea Will Not Pursue Compulsory Licensing Against MNCs, But For How Long?
South Korea Will Not Pursue Compulsory Licensing Against MNCs, But For How Long?
South Korea Govt Proposes “Refund System” To Keep MNC Drug Prices Up, Provide Access To Patients
Sanofi Asks Thailand To Review Compulsory Licensing Policy
Advertisement
UsernamePublicRestriction

Register

SC070998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel